XTL Biopharmaceuticals   Report issue

For profit Phase 1 Phase 2
Founded: Herzliya Israel (1993)
Status: Left NME R&D (2017)

Organization Overview

First Clinical Trial
2005
NCT00300807
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Alternative names

XTL Bio

Active Ingredients

Drugs in Phase 2 Trials (1)

bicifadine (2 trials)

Drugs in Phase 1 Trials (3)

hcv-abxtl65 (1 trial)

hcv-abxtl68 (1 trial)

xtl-2125 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Neuropathies (Phase 2)

Hepatitis (Phase 1)

Hepatitis A (Phase 1)

Hepatitis C (Phase 1)

Hepatitis C, Chronic (Phase 1)

Neuralgia (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Virus Diseases (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4